2015-2019 German Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing Markets: Country Forecasts, Emerging Technologies, Competitive Strategies

September 2015 | 407 pages | ID: 206AD75D18FEN
Venture Planning Group

Abstracts

Complete report $1,850. DataPack (test volumes, sales forecasts, supplier shares) $1,200. The report is available by section, market segment, and can be custom-tailored to your specific information needs and budget.

This new study from VPGMarketResearchcontains 407 pages, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities for molecular diagnostic technologies and products in testing for genetic diseases, cancer, as well as forensic and paternity/HLA typing applications during the next five years.

Report Highlights

• Market shares of leading suppliers
• Business and technological trends in major markets
• Five-year test volume and sales forecasts
• Market shares of leading competitors
• Feature comparison of major analyzers
• Strategic profiles of leading market players and start-up firms developing innovative products
• Specific product and business opportunities for instrument and consumable suppliers.

Rationale

Genetic Diseases, Cancer, Forensic and Paternity molecular diagnostic testing markets are among the most rapidly growing segments of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by these markets, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

Germany Market Overview

• Laboratories performing DNA sequencing and molecular diagnostic testingby country and market segment.
• Five-year test volume and sales projections.

Market Segmentation Analysis

• Five-year test volume and sales projections:
• Infectious Diseases - Forensic Testing
• Cancer - Paternity Testing/HLA Typing
• Genetic Diseases - Others
• A comprehensive analysis of the sequencing market by laboratory segment.
• Detailed market segmentation analysis, including review of the market dynamics, trends, structure, size, growth and major suppliers.

Product/Technology Review

• Comparison of the major molecular diagnosticanalyzers.
• Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and over target/signal amplification methods.
• Worldwide listings of companies, universities and research centers developing new molecular diagnostictechnologies and products.

Competitive Assessments

Extensive strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new technologies/products in R&D.

• Abbott
• Affymetrix
• Agilent Technologies
• Applied Gene Technologies
• Arca Biopharma
• Beckman Coulter/Danaher
• Becton Dickinson
• Biokit
• BioMerieux
• Bio-Rad
• Biotest
• Cepheid
• CellMark Forensics Lab/Corp
• Decode Genetics
• Diadexus
• Eiken
• Elitech Group
• Enzo
• Exact Sciences
• Fujirebio
• Grifols
• Hologic/Gen-Probe
• Illumina
• Kreatech/Leica
• Li-Cor Biosciences
• Monogram Biosciences
• Myriad Genetics
• Ortho-Clinical Diagnostics
• Perkin Elmer/Caliper
• Proteome Sciences
• Qiagen
• Roche
• Scienion
• Sequenom
• Shimadzu
• Siemens
• Sierra Molecular
• Takara Bio
• Tecan Group
• Thermo Fisher

Comprehensive listings of companies developing and marketing molecular diagnostic products, by test and application.

Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.
• Business planning issues and concerns.

Contains 407 pages

Contents

INSTRUMENTATION REVIEW

  ABBOTT AXSYM
  ABBOTT IMX/IMX SELECT
  ABBOTT LCX
  ANAGEN AN2000/AURAFLEX
  BECKMAN COULTER ACCESS
  BECKMAN COULTER/BIOMEK FK
  BIOCHEM PHARMA/SR1
  BIOMERIEUX/VITEK VIDAS
  BIORAD GENESCOPE
  BIOTROL SYSTEM 7000
  GENPROBE TIGRIS
  J&J DIAGNOSTICS/AMERSHAM AMERLITE
  J&J DIAGNOSTICS VITROS ECI
  OLYMPUS PK310
  ROCHE COBAS CORE
  ROCHE COBAS AMPLICOR
  ROCHE ELECSYS 1010/2010
  ROCHE ES
  ROCHE ES
  ROCHE ES 300/300AL
  SIEMENS ACS: CENTAUR
  SIEMENS ACS:
  SIEMENS ELISA PROCESSOR II/III
  SIEMENS IMMUNO
  SIEMENS/OPUS/PLUS/MAGNUM
  SIEMENS STRATUS
  TECAN LS SERIES
  TOSOH AIA1200/1200DX/NEXIA/600
  WALLAC/PHARMACIA DELFIA

COMPETITIVE PROFILES

Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
BioRad
Cepheid
Diamedix
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
Hologic/GenProbe
ID Biomedical
Kreatech/Leica
Lonza
OrthoClinical Diagnostics
Qiagen
Roche
Scienion
Sequenom
SeraCare
Siemens
Takara Bio
Thermo Fisher
Wallac
Wako